Loading clinical trials...
Loading clinical trials...
A First-In-Human, Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled, Single- and Multiple-Dose, Dose-Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants
Conditions
Interventions
UCB8600
Placebo
Locations
1
Bulgaria
Up0086 001
Sofia, Bulgaria
Start Date
June 30, 2020
Primary Completion Date
August 2, 2021
Completion Date
August 2, 2021
Last Updated
July 19, 2022
NCT07358364
NCT06931405
NCT06873516
NCT07230418
NCT07219615
NCT07021495
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions